FDA ALERT
FDA ALERT
09/13/2024
Jessica Ganga
In June, following a placebo-controlled trial, the FDA approved pembrolizumab with chemotherapy to treat patients with primary advanced or recurrent endometrial carcinoma.
09/13/2024
FDA Alert
FDA Alert
04/22/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.
04/22/2024
FDA Alert
FDA Alert
03/04/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
03/04/2024
FDA ALERT
FDA ALERT
01/26/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
01/26/2024
fda alert
fda alert
10/19/2023

Leigh Precopio

Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
FDA Alert
FDA Alert
09/11/2023

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approval follows a single-arm, multicenter, open-label trial in 91 patients with uveal melanoma with unresectable hepatic metastases.
09/11/2023
Bladder Cancer
Bladder Cancer
01/04/2023
The FDA’s approval of the first gene therapy to treat high-risk non-muscle-invasive bladder cancer follow a multicenter clinical trial.
01/04/2023
Oncology
Oncology
09/25/2017
The US Food and Drug Administration (FDA) has indicated nivolumab for intravenous use in patients with previously treated liver cancer.
09/25/2017
Oncology
Oncology
09/25/2017
The US Food and Drug Administration (FDA) expanded the approval of a targeted therapy to treat gastric or gastroesophageal junction (GEJ) cancer.
09/25/2017
Breast cancer
Breast cancer
08/28/2017
The US Food and Drug Administration has expanded the approval of Faslodex, a hormonal therapy for the treatment of breast cancer first approved in 2002.
08/28/2017